Clinical Application of Inhibin A Measurement: Prenatal Serum Screening for Down Syndrome

Inhibin A is secreted in significant quantities by the corpus luteum and fetoplacental unit, suggesting a role in fertility and pregnancy. Negative feedback regulation of follicle-stimulating hormone during pregnancy is one expected function of inhibin A, but the complete repertoire of actions of this hormone in pregnancy, including paracrine and autocrine actions, is yet to be fully understood. Inhibin A levels have been carefully described throughout normal pregnancy and studied in association with maternal and fetal complication such as intrauterine growth restriction, preterm labor or delivery, and preeclampsia. The first clinical application of inhibin A measurement in pregnancy has been its use as a second-trimester maternal serum marker for Down syndrome. Our laboratory was among the first, in 1998, to implement Quad marker screening, inhibin A measurement in conjunction with α-fetoprotein, unconjugated estriol, and human chorionic gonadotropin, to assess patients' risk of having a Down syndrome baby. The test performance of the Quad test has been validated by several large studies, detecting about 80% of Down syndrome pregnancies at a 5% false-positive rate. The present review describes Down syndrome and the use of inhibin A in second-trimester prenatal screening. We also address the method used for inhibin A measurement, the biology of inhibin A in Down syndrome pregnancy, and the effects of covariates and other fetal abnormalities on inhibin A levels.

KEYWORDS

Inhibin A - pregnancy - screening - Down syndrome

REFERENCES

• 1 Ward O C. John Langdon Down: A Caring Pioneer. London, UK; The Royal Society of Medicine Press 1998
• 2 Noble J. Natural history of Down’s syndrome: a brief review for those involved in antenatal screening.  J Med Screen. 1998;  5 172-177
• 3 Wald N. Down’s syndrome. In: Wald N, Leck I Antenatal and Neonatal Screening Oxford; Oxford University Press 2000: 85-115
• 4 Hook E B, Cross P K, Schreinemachers D M. Chromosomal abnormality rates at amniocentesis and in live-born infants.  JAMA. 1983;  249 2034-2038
• 5 Cuckle H S, Wald N J, Lindenbaum R H. Maternal serum alpha-fetoprotein measurement. A screening test for Down syndrome.  Lancet. 1984;  1 926-929
• 6 Canick J, Knight G J, Palomaki G E et al.. Low second trimester maternal serum unconjugated estriol in pregnancies with Down’s syndrome.  Br J Obstet Gynaecol. 1988;  95 330-333
• 7 Wald N J, Cuckle H S, Densem J W et al.. Maternal serum unconjugated oestriol as an antenatal screening test for Down’s syndrome.  Br J Obstet Gynaecol. 1988;  95 334-341
• 8 Bogart M, Pandian M R, Jones O W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities.  Prenat Diagn. 1987;  7 623-630
• 9 Wald N J, Cuckle H S, Densem J W et al.. Maternal serum screening for Down’s syndrome in early pregnancy.  BMJ. 1988;  297 883-887
• 10 Wald N J, Kennard A, Hackshaw A et al.. Antenatal screening for Down’s syndrome.  J Med Screen. 1997;  4 181-246
• 11 Groome N, O’Brien M. Immunoassays for inhibin and its subunits.  J Immunol Methods. 1993;  165 167-176
• 12 Wald N J, Rodeck C, Hackshaw A K, Walters J, Chitty L, Mackinson A M. First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine, and Ultrasound Screening Study (SURUSS).  J Med Screen. 2003;  10 56-104
• 13 Groome N P, Illingworth P J, O’Brien M et al.. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay.  Clin Endocrinol (Oxf). 1994;  40 717-723
• 14 Lambert-Messerlian G M, Halle J E, Sluss P M et al.. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay.  J Clin Endocrinol Metab. 1994;  79 45-50
• 15 Wallace E M, Crossley J A, Ritoe S C, Aitken D A, Spencer K, Groome N P. Evolution of an inhibin A ELISA method: implications for Down’s syndrome screening.  Ann Clin Biochem. 1998;  35 656-664
• 16 Knight G J, Palomaki G E, Neveux L M, Haddow J E, Lambert-Messerlian G M. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down’s syndrome screening.  J Med Screen. 2001;  8 2-7
• 17 Wald N J, Densem J W, George L, Muttukrishna S, Knight P G. Prenatal screening for Down’s syndrome using inhibin-A as a serum marker.  Prenat Diagn. 1996;  16 143-153
• 18 Watt H C, Wald N J, George L. Maternal serum inhibin-A levels for twin pregnancies: implications for screening for Down’s syndrome.  Prenat Diagn. 1996;  16 927-929
• 19 Watt H C, Wald N J, Smith D et al.. Effect of allowing for ethnic group in prenatal screening for Down’s syndrome.  Prenat Diagn. 1996;  16 691-698
• 20 Wallace E M, Crossley J A, Ritoe S C, Groome N P, Aitken D A. Maternal serum inhibin-A in pregnancies complicated by insulin dependent diabetes mellitus.  Br J Obstet Gynaecol. 1997;  104 946-948
• 21 Wald N J, Watt H C, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down’s syndrome.  Prenat Diagn. 1996;  16 923-926
• 22 Wald N J, White N, Morris J K, Huttly W J, Canick J A. Serum markers for Down’s syndrome in women who have had in vitro fertilisation: implications for antenatal screening.  Br J Obstet Gynaecol. 1999;  106 1304-1306
• 23 Maymon R, Shulman A. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies.  Prenat Diagn. 2004;  24 125-129
• 24 Ferriman E L, Sehmi I K, Jones R, Cuckle H S. The effect of smoking in pregnancy on maternal serum inhibin A levels.  Prenat Diagn. 1999;  19 372-374
• 25 Palomaki G E, Knight G J, Haddow J E, Canick J A, Wald N J, Kennard A. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol and hCG: impact on Down syndrome screening.  Obstet Gynecol. 1993;  81 675-678
• 26 Maymon R, Sehmi I K, Herman A, Jones R G, Sherman D, Cuckle H. Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome.  Prenat Diagn. 2000;  20 12-16
• 27 Ferriman E L, Sehmi I K, Jones R, Railton A , Hilton R C, Cuckle H S. False-positive maternal serum screening in systemic lupus erythematosus: a case report.  Prenat Diagn. 2000;  20 851-856
• 28 Bazzett L B, Yaron Y, O’Brien J E et al.. Fetal gender impact on multiple marker screening results.  Am J Med Genet. 1998;  76 369-371
• 29 Lam Y H, Tang M H. The effect of fetal gender on second-trimester maternal serum inhibin-A concentration.  Prenat Diagn. 2001;  21 662-664
• 30 Van Lith J MM, Pratt J J, Beekhuis J R, Mantingh A. Second trimester maternal serum immunoreactive inhibin as a marker for fetal Down’s syndrome.  Prenat Diagn. 1992;  12 801-806
• 31 Spencer K, Wood P J, Anthony F W. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down’s syndrome.  Ann Clin Biochem. 1993;  30 219-220
• 32 Cuckle H S, Holding S, Jones R. Maternal serum inhibin levels in second trimester Down’s syndrome pregnancies.  Prenat Diagn. 1994;  14 387-390
• 33 Lambert-Messerlian G M, Canick J A, Palomaki G E, Schneyer A L. Second trimester levels of maternal serum inhibin A, total inhibin, α inhibin precursor and activin in Down’s syndrome pregnancy.  J Med Screen. 1996;  3 58-62
• 34 Cuckle H S, Holding S, Jones R, Wallace E M, Groome N P. Maternal serum dimeric inhibin A in second-trimester Down’s syndrome pregnancies.  Prenat Diagn. 1995;  15 385-386
• 35 D’Antona D, Wallace E M, Shearing C, Ashby J P, Groome N P. Inhibin A and pro-αC inhibin in Down syndrome and normal pregnancies.  Prenat Diagn. 1998;  18 1122-1126
• 36 Thirunavukarasu P, Lambert-Messerlian G, Robertson D M, Dawson G, Canick J, Wallace E M. Molecular weight forms of inhibin A, inhibin B and pro-C in maternal serum, amniotic fluid and placental extracts of normal and Down syndrome pregnancies.  Prenat Diagn. 2002;  22 1086-1092
• 37 Debieve F, Beerlandt S, Hubinont C, Thomas K. Gonadotropins, prolactin, inhibin A, inhibin B, and activin A in human fetal serum from midpregnancy and term pregnancy.  J Clin Endocrinol Metab. 2000;  85 270-274
• 38 Wallace E M, Crossley J A, Groome N P, Aitken D A. Amniotic fluid inhibin-A in chromosomally normal and Down’s syndrome pregnancies.  J Endocrinol. 1997;  152 109-112
• 39 Dalgliesh G L, Aitken D A, Lyall F, Howatson A G, Connor J M. Placental and maternal serum inhibin-A and activin-A levels in Down’s syndrome pregnancies.  Placenta. 2001;  22 227-234
• 40 Lambert-Messerlian G M, Luisi S, Florio P, Mazza V, Canick J A, Petraglia F. Second trimester levels of maternal serum total activin A and placental inhibin/activin α and βA subunit messenger ribonucleic acids in Down syndrome pregnancy.  Eur J Endocrinol. 1998;  138 425-429
• 41 Lambert-Messerlian G M, Canick J A, Palomaki G E. Maternal serum total activin A in pregnancies affected with fetal Down’s syndrome [letter].  J Med Screen. 1996;  3 217
• 42 Cuckle H S, Sehmi I, Jones R, Evans L W. Maternal serum activin A and follistatin levels in pregnancies with Down syndrome.  Prenat Diagn. 1999;  19 513-516
• 43 Wallace E M, Riley S C, Crossley J A et al.. Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy.  J Clin Endocrinol Metab. 1997;  82 218-222
• 44 Lambert-Messerlian G M, Palomaki G E, Canick J A. Second trimester levels of maternal serum inhibin A in pregnancies affected by fetal neural tube defects.  Prenat Diagn. 2000;  20 680-682
• 45 Palomaki G E, Haddow J E, Knight G E et al.. Risk-based screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin.  Prenat Diagn. 1995;  15 713-723
• 46 Aitken D A, Wallace E M, Crossley J A et al.. Dimeric inhibin A as a marker for Down syndrome in early pregnancy.  N Engl J Med. 1996;  334 1231-1236
• 47 Lambert-Messerlian G M, Saller Jr D N, Tumber M B, French C A, Peterson C J, Canick J A. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops.  Prenat Diagn. 1998;  18 1061-1067
• 48 Cuckle H S, Sehmi I K, Jones R G. Inhibin A and non-Down syndrome aneuploidy.  Prenat Diagn. 1999;  19 787-792
• 49 Saller Jr D N, Canick J A, Blitzer M G et al.. Second-trimester maternal serum analyte levels associated with fetal trisomy 13.  Prenat Diagn. 1999;  19 813-816
• 50 Hsu J, Chiang C, Hsieh C, Hsieh T. Elevated second-trimester maternal serum inhibin A levels in Asian pregnancies with fetal Down syndrome and other chromosomal abnormalities.  Fetal Diagn Ther. 2003;  18 105-110
• 51 Watanabe H, Hamada H, Yamada N et al.. Second-trimester maternal pregnancy-associated plasma protein A and inhibin A levels in fetal trisomies.  Fetal Diagn Ther. 2002;  17 137-141
• 52 Lambert-Messerlian G M, Saller D N, Tumber M B et al.. Second trimester maternal serum and inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops.  Prenat Diagn. 1998;  18 1061-1067
• 53 Saller Jr D N, Canick J A, Oyer C E. The detection of non-immune hydrops through second-trimester maternal serum screening.  Prenat Diagn. 1996;  16 431-435
• 54 Benn P A, Egan J F, Ingardia C J. Extreme second-trimester serum analyte values in Down syndrome pregnancies with hydrops fetalis.  J Matern Fetal Neonatal Med. 2002;  11 262-265
• 55 Oyer C E, Canick J A. Maternal serum hCG levels in triploidy: variability and need to consider molar tissue.  Prenat Diagn. 1992;  12 627-629
• 56 Benn P A, Gainey A, Ingardia C J, Rodis J F, Egan J FX. Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement.  Prenat Diagn. 2001;  21 680-686
• 57 Connor J M, Ferguson-Smith M A. Essential Medical Genetics 2nd ed. Oxford, UK; Blackwell Scientific 1987: 177
• 58 Aitken D A, Ireland M, Berry E et al.. Second-trimester pregnancy associated plasma protein A levels are reduced in Cornelia de Lange syndrome pregnancies.  Prenat Diagn. 1999;  19 706-710
• 59 Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.  Prenat Diagn. 1999;  19 1035-1042
• 60 Haddow J E, Palomaki G E, Knight G J et al.. Screening of maternal serum for fetal Down’s syndrome in the first trimester.  N Engl J Med. 1998;  338 955-961
• 61 Wald N J, Hackshaw A K. Combining ultrasound and biochemistry in first-trimester screening for Down’s syndrome.  Prenat Diagn. 1997;  17 821-830
• 62 Malone F D, Wald N J, Canick J A et al.. First- and second-trimester evaluation of risk (FASTER) trial: principal results of the NICHD multicenter Down syndrome screening study.  Am J Obstet Gynecol. 2003;  189 S56
• 63 Wald N J, Rodeck C, Hackshaw A K, Walters J, Chitty L, Mackinson A M. First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).  J Med Screen. 2003;  10 56-104
• 64 Spencer K, Liao A W, Ong C YT, Geerts L , Nicolaides K H. Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester.  Prenat Diagn. 2001;  21 441-444
• 65 Noble P L, Wallace E M, Snijders R JM, Groome N P, Nicolaides K H. Maternal serum inhibin-A and free β-hCG concentrations in trisomy 21 pregnancies at 10 to 14 weeks of gestation.  Br J Obstet Gynaecol. 1997;  104 367-371
• 66 Wallace E M, Grant V E, Swanston I A, Groome N P. Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down’s syndrome.  Prenat Diagn. 1995;  15 359-362
• 67 Wald N J, George L, Smith D, Densem J W, Petterson K. Serum screening for Down’s syndrome between 8 and 14 weeks of pregnancy.  Br J Obstet Gynaecol. 1996;  103 407-412
• 68 Lambert-Messerlian G M, Palomaki G E, Knight G J, Neveux L M, Canick J A, Haddow J E. Dimeric inhibin-A as a marker for Down syndrome in the first trimester. Annual Meeting of the American College of Medical Genetics; March 4-7 2004 Orlando, FL;
• 69 Stranc L C, Evans J A, Hamerton J L. Chorionic villus sampling and amniocentesis for prenatal diagnosis.  Lancet. 1997;  349 711-714
• 70 Wald N J, Watt H C, Hackshaw A K. Integrated screening for Down’s syndrome based on tests performed during the first and second trimesters.  N Engl J Med. 1999;  341 461-467
• 71 Muttukrishna S, George L, Fowler P A, Groome N P, Knight P G. Measurement of serum concentration of inhibin-A (α-βA dimer) during human pregnancy.  Clin Endocrinol (Oxf). 1995;  42 391-397
• 72 Reis F M, D’Antona D, Petraglia F. Predictive value of hormone measurements in maternal and fetal complications of pregnancy.  Endocr Rev. 2002;  23 230-257
• 73 Lambert-Messerlian G. Physiology and pathophysiology of inhibin A and activin A in human pregnancy.  Curr Opin Endocrinol Diabetes. 2000;  7 337-344